Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of January 2021, specifically dated January 29, 2021. The registrant is a foreign private issuer based in Jerusalem, Israel, operating in the pharmaceutical sector.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial event disclosed is a capital raise:
- Capital Raised: $12.1 million
- Instrument: Follow-on underwritten offering of American Depositary Shares (ADS)
- Liquidity Impact: The filing text does not specify the company's total cash balance or liquidity position prior to or after this transaction.
Material Changes
The material change reported is the execution of the $12.1 million equity offering. No comparative financial data or operational changes versus prior periods are included in this specific filing text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, risk factors, or contingencies. It serves solely to announce the pricing of the offering and incorporates the associated press release by reference.
Investor Verification Checklist
- Verify the final number of ADS shares issued in the $12.1 million offering.
- Confirm the use of proceeds as detailed in the referenced Press Release (Exhibit 99.1).
- Check the company's updated cash position and burn rate in subsequent filings (e.g., Form 20-F or 10-Q).
- Review the underwriting agreement for any lock-up periods or over-allotment options.